GlassScriptPhysician profile
Fahima Nadi
NPI 1770072290
$3,334.12
in general payments reported to CMS, 2019-2025
16 companies · $1,670 in 2025
The $1,670 reported for 2025 was more than what 84% of Sleep Medicine (Internal Medicine) providers received nationally (typical 2025 total: $447).
See the full distribution for Sleep Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $19.80 · 2023: $493 · 2024: $1,151 · 2025: $1,670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,138 · Education: $167 · Travel and Lodging: $8.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,138.46 |
| Education | $166.99 |
| Travel and Lodging | $8.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $651.25 | 2023-2025 | Inspire |
| Jazz Pharmaceuticals INC. | $628.03 | 2023-2025 | |
| Harmony Biosciences LLC | $452.01 | 2023-2025 | Wakix |
| Lilly USA, LLC | $377.55 | 2025 | Zepbound, Mounjaro |
| Novartis Pharmaceuticals Corporation | $277.44 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $229.32 | 2024 | Farxiga, Andexxa |
| Dexcom, INC. | $155.17 | 2025 | Dexcom G6 Transmitter |
| Boston Scientific Corporation | $146.48 | 2025 | Watchman |
| Novo Nordisk INC | $78.26 | 2025 | Wegovy |
| Resmed Corp | $76.80 | 2022-2024 | |
| Depuy Synthes Sales INC. | $66.91 | 2025 | Orthovisc |
| Axsome Therapeutics, INC. | $62.26 | 2023 | Sunosi |
| 3b Medical, INC. | $52.09 | 2024-2025 | Luna |
| Shield Therapeutics INC | $38.69 | 2025 | |
| Avadel Cns Pharmaceuticals, LLC | $24.63 | 2024 | Lumryz |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cipher Pharmaceuticals US LLC | $17.23 | 2025 | Spinosad, Natroba |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fahima Nadi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.